News

“IAS – the International AIDS Society – warmly welcomes the news that a COVID-19 vaccine will soon also be produced in South Africa. Suffering driven by vaccine inequity would largely be a thing of the past if low- to middle-income countries had the capacity to control the production and distribution of life-saving vaccines. “But this good news comes with caveats. To truly empower low- to middle-income countries in the response to COVID-19 and future pandemics, the transfer of technologies ...

Helen McDowell has been elected as the ILF industry representative. Helen, who has worked in HIV for over 15 years, leads global public policy, access to medicine, advocacy and global public health initiatives, including public-private partnerships, for ViiV Healthcare. She is also an active member of GSK’s (ViiV’s majority shareholder) Global Health Leadership team. “At ViiV Healthcare, we have long believed in the impact and power of taking a partnership approach to tackling global health ...

Monday, 26 April 2021 (Geneva, Switzerland): IAS – the International AIDS Society – welcomes the appointment of its President, AdeebaKamarulzaman, to the newly formed World Health Organization (WHO) Science Council.   The Science Council will advise WHO on high-priority scientific issues that could have a direct impact on global health.   “Science must be at the heart of everything we do as global health advocates,” Kamarulzaman said. “Like the HIV pandemic, the COVID-19 pandemic has demo...

It is my great honour to announce that Dr Birgit Poniatowski is the next Executive Director of IAS – the International AIDS Society. She assumes the role with immediate effect.

New results announced today by ViiV healthcare show that injection of long-acting pre-exposure prophylaxis (PrEP) cabotegravir every two months is 89% more effective than a daily Truvada oral pill (emtricitabine/tenofovir disoproxil fumarate) in a trial of women at increased risk of HIV acquisition.

Countering the COVID-19 infodemic requires not only facts, but also the coordinated and strategic advocacy for which those fighting HIV are renowned. Now more than ever, scientists need to counter lies and myths, and defend the integrity and independence of their enterprise. The emergence of the SARS-CoV-2 virus has not only led to the global COVID-19 pandemic, but also fueled an accompanying onslaught of misinformation. Some have promoted drugs such as hydroxychloroquine as cures for the disea...

Cori Vail has been elected as the ILF industry representative. Cori currently leads HIV Access Strategy & Impact efforts as part of Johnson & Johnson’s Global Public Health team. In this role, she is responsible for developing and executing insight-based strategies to accelerate adoption of transformational HIV innovation for underserved populations in resource-limited settings. Cori joined the Johnson & Johnson family of companies in 2003 and held numerous roles across engineering,...

It is with sadness and much gratitude that, on behalf of IAS - the International AIDS Society - Governing Council, I am letting you know that IAS Executive Director Kevin Osborne has announced his departure from the organization. After close to five successful years at the IAS, first as Director of HIV Programmes and Advocacy, and then as Executive Director, Kevin will depart at the end of September 2020 to join his partner abroad. With Kevin at the helm, the organization has benefited from his...

IAS has announced nine newly elected and three re-elected members to its Governing Council. Adeeba Kamarulzaman of Malaysia is the new IAS President and Sharon Lewin of Australia the President-Elect, with Jennifer Kates of the United States serving as Treasurer. “The new members joining the IAS Governing Council add a great diversity of skills and experiences,” IAS President Adeeba Kamarulzaman said. “They will be pivotal in steering IAS into the future and dealing with a fast-changing scien...

3 February 2020 (Geneva, Switzerland) - The Global HIV Vaccine Enterprise (the Enterprise), hosted by the International AIDS Society (IAS), shares the deep disappointment that the Phase 2b/3 HIV vaccine study HVTN 702 has been stopped by the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID).